FPRX Stock UPDATES Five Prime Therapeutics Inc (FPRX) 12.28 09/12/2014

New Post Public Reply Private Reply Replies (0) Message Board

Sep 12, 2014 at 6:29 AM

Five Prime Therapeutics Inc (FPRX) 12.28 $FPRX

Five Prime Therapeutics to Present at Morgan Stanley 2014 Global Healthcare Conference
GlobeNewswire - Wed Sep 03, 12:29PM CDT
Five Prime Therapeutics, Inc. (Nasdaq:FPRX) (Five Prime), a clinical-stage biotechnology company focused on discovering and developing novel protein therapeutics for cancer and inflammatory diseases, today announced that Lewis T. "Rusty" Williams, M.D., Ph.D., President and Chief Executive Officer of Five Prime, will present at the Morgan Stanley 2014 Global Healthcare Conference on Tuesday, September 9 at 5:15 PM Eastern Time. The conference will take place at the Grand Hyatt in New York City.

How Five Prime Therapeutics (FPRX) Stock Stands Out in a Strong Industry - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Sep 03, 7:33AM CDT
Five Prime Therapeutics (FPRX) is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective. It currently has a Zacks Industry Rank of 72 out of more than 250 industries.

Five Prime Therapeutics (FPRX) Jumps: Stock Adds 10.3% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Aug 12, 7:51AM CDT
Five Prime Therapeutics, Inc. (FPRX) was a big mover last session, as its shares rose over 10% on the day.

Small companies lead the I-O class of Cancer Therapies
ACCESSWIRE - Fri Aug 08, 7:02AM CDT
Los Angeles, CA / August 8, 2014 / Tumor cells, tending to persist after treatment, lead to remission and have been a bane to cancer researchers and doctors for decades. Only recently, immuno-oncology, labeled 'I-O' first by Bristol-Myers Squibb Company (NYSE:BMY) has emerged to become a new class of cancer medicines that may someday take a meaningful place alongside chemotherapy, surgery, and radiation.

Five Prime Therapeutics Announces Second Quarter 2014 Financial Results
GlobeNewswire - Tue Aug 05, 3:09PM CDT
Five Prime Therapeutics, Inc. (Nasdaq:FPRX) (Five Prime), a clinical-stage biotechnology company focused on discovering and developing novel protein therapeutics for cancer and inflammatory diseases, today provided a corporate update and reported financial results for the second quarter that ended June 30, 2014.

Five Prime Therapeutics to Announce Second Quarter Financial Results and Host Conference Call on August 5, 2014
GlobeNewswire - Tue Jul 29, 3:12PM CDT
Five Prime Therapeutics, Inc. (Nasdaq:FPRX) (Five Prime), a clinical-stage biotechnology company focused on discovering and developing novel protein therapeutics for cancer and inflammatory diseases, will report its second quarter 2014 financial results on Tuesday, August 5, 2014, after the U.S. financial markets close. Five Prime will host a conference call and live audio webcast on Tuesday, August 5, 2014 at 5:00 p.m. (ET)/2:00 p.m. (PT) to discuss the company's financial results and provide a general business update.

Why Is Wall Street Gobbling Up These 2 Small-Cap Biotech Stocks?
George Budwell, The Motley Fool - Motley Fool - Tue Jul 08, 9:55AM CDT
When institutional investors start buying large blocks of shares in a company, it could be a good sign that the stock is getting positive attention because of its potential to move higher. In the last quarter, we saw institutions dramatically...

Five Prime Therapeutics to Present at the 13th Annual Needham Healthcare Conference
GlobeNewswire - Tue Apr 01, 5:52PM CDT
Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing novel protein therapeutics for cancer and inflammatory diseases, today announced that Aron Knickerbocker, Chief Business Officer, will present at the 13 Annual Needham Healthcare Conference on April 8, 2014 at 4:20 PM Eastern Time. The conference will take place at the Westin Grand Central Hotel in New York City.

Five Prime Therapeutics Announces Upcoming Presentations at the 2014 American Association for Cancer Research Meeting
GlobeNewswire - Thu Mar 27, 6:28PM CDT
Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing novel protein therapeutics for cancer and inflammatory diseases, today announced that data related to FP-1039 (GSK3052230), an FGF ligand trap in a global, multi-arm Phase 1b study, and FPA144, a monoclonal antibody against the FGF receptor 2b, will be presented at the American Association for Cancer Research (AACR) Annual Meeting. The meeting will be held April 5-9, 2014 in San Diego, CA.

Big Pharma's Not-So-Hidden Secret to Success
Sean Williams, The Motley Fool - Motley Fool - Thu Mar 27, 11:05AM CDT
The past week may have been a bit of a bumpy ride for the pharmaceutical and biotech sector following congressional testimony that highlighted the rising cost of branded drugs, but it represents nothing more than a tiny hurdle in what's been an...

Bristol Myers Deal Overshadows Q4 loss at Five Prime - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 27, 10:00AM CDT
Amidst the excitement about the Bristol-Myers deal, Five Prime reported its fourth quarter 2013 results.

Biotech Stock Roundup: GILD Letter Triggers Major Selloff - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Mar 26, 9:13AM CDT
Are the good days over for the biotech sector or is this just a correction?

Five Prime Therapeutics posts higher net loss of USD28.9m in fiscal 2013
M2 - Wed Mar 26, 6:02AM CDT
US-based biotechnology company Five Prime Therapeutics (NasdaqGS:FPRX) stated on Tuesday net loss of USD28.9m (USD5.23 per basic and diluted share) for the year ended 31 December 2013.

Five Prime Therapeutics Announces Fourth Quarter and Fiscal 2013 Financial Results
GlobeNewswire - Tue Mar 25, 3:30PM CDT
Five Prime Therapeutics, Inc. (Nasdaq:FPRX) (Five Prime), a clinical-stage biotechnology company focused on discovering and developing novel protein therapeutics for cancer and inflammatory diseases, today provided a corporate update and reported financial results for the fourth quarter and year ended Dec. 31, 2013.

This Week in Biotech: Endocyte Doubles, Intercept Wobbles, and Geron Gets Smacked Again
Sean Williams, The Motley Fool - Motley Fool - Sat Mar 22, 12:45PM CDT
With the SPDR S&P Biotech Index up 57% over the trailing-12-month period , it's evident that investment dollars are willingly flowing into the biotech sector. Keeping that in mind, let's have a look at some of the rulings, studies, and...

Earnings Release and Presentation Schedules, Nominations, and Financial Results - Analyst Notes on Five Prime Therapeutics, Acceleron, Emergent BioSolutions, CONMED, and ImmunoGen
PR Newswire - Fri Mar 21, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Five Prime Therapeutics, Inc. (NASDAQ: FPRX), Acceleron Pharma Inc. (NASDAQ: XLRN), Emergent BioSolutions Inc. (NYSE: EBS), CONMED Corporation (NASDAQ: CNMD), and ImmunoGen, Inc. (NASDAQ: IMGN). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register

Five Prime Therapeutics to Present at Future Leaders in the Biotech Industry
GlobeNewswire - Thu Mar 20, 3:12PM CDT
Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing novel protein therapeutics for cancer and inflammatory diseases, today announced that Lewis T. "Rusty" Williams, M.D., Ph.D., President and Chief Executive Officer of Five Prime, will present at the 21 Annual Future Leaders in the Biotech Industry conference on Friday, March 28, at 8:30 a.m. Eastern Time. The conference will take place at the Millennium Broadway Hotel in New York City.

Biotech Stock Roundup: Biogen Up for S&P100, Geron Plunges on Clinical Hold - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Mar 19, 12:27PM CDT
Last week's highlights include Biogen's addition to S&P100, the FDA clinical hold on Geron's sole pipeline candidate and an improved outlook from Alexion.

Can the Uptrend Continue for Five Prime (FPRX)? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Mar 19, 8:27AM CDT
Can the Uptrend Continue for Five Prime (FPRX)?

Five Prime, Bristol-Myers Squibb Cut $350M Immuno-Oncology Deal
Ben Fidler, The Motley Fool - Motley Fool - Tue Mar 18, 5:30PM CDT
Five Prime Therapeutics didn't spring out of the blocks like many of the other members of biotech's IPO class of 2013 . But the South San Francisco, CA-based biotech is now having its day in the sun, because it just cut a deal worth up to $350...

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

HANGCHA's AI-Fork Revolution: Bold Steps to 2030

Forklifts and the Future: A Fork in the Road for HANGCHA There's a movement happening, folks, and I don't mean in the usual stock ticker shift way. We're talking forklifts here—AI-powered, no less. HANGCHA Group, a name that may or may not roll off the tongue but sure makes waves in manufacturing, just held its 4th Global Dealers Conference in Hangzhou, China. If you're...

GrayMar’s Strategic Southeast Boost Could Reshape Market

GrayMar’s Big Southeast Step Alright, let’s face it—when a company like GrayMar Environmental Services decides to go on a shopping spree, it’s a signal worth heeding, especially if they’ve got their eyes on expanding their empire across the Southeast. This time, it’s not just another map pin but a strategic play with heft. GrayMar’s picked up six locations...

Jing'an District Drives Bold Investments at 2026 CIIE

Jing'an's Strategic Moves at 2026 CIIE When you hear "Shanghai," you probably think bright lights, bustling streets, and a city that never sleeps. Now narrow that down even further and you get Jing'an District—a place that's climbing the ladder not just in glitz, but in strategic moves that matter. This year, during the China International Import Expo (CIIE), Jing'an...

CREB Unlocks 8.50% APY Bonds for IRA Investors

CRET Broadens the Path to Fixed-Income Security If you're the type who gets a rash just thinking about stock market jitters, pay attention: Compound Real Estate Bonds (CREB) has cracked the door open a bit wider for your retirement peace of mind. They've teamed up with Equity Trust to offer their rock-solid 8.50% APY bonds through self-directed IRAs. That's right—these...

Munters Updates Financial Targets Amid Growth Plans

Munters' Bold New Targets and Strategic Moves Ever feel like you're on a constant treadmill chasing numbers? Munters Group knows the feeling. Over in Stockholm, they've just laid out fresh strategies at their Capital Markets Day—not just any pie-in-the-sky type goals, but heavy hitters that are setting the tone for their future. CEO Stefan Aspman is all geared up,...

Legal Titans Join Las Vegas Economic Board: Strategic Moves

Legal Minds Stepping into Economic Turf in Las Vegas Out in the shimmering lights of Las Vegas, there's more than blackjack tables causing a stir. Joel Tasca from Greenberg Traurig, a law giant, now sits on the board of the Las Vegas Regional Economic Partnership (LVREP), marking a notable shift in local economic strategizing. Meanwhile, seasoned attorney Michael Bonner...

Minerva Foods' Profit Struggles Despite Revenue Growth

Setting the Stage: Minerva Foods' Latest Report Walking through the jungle of financial statements, few things are clear-cut. Minerva Foods handed out its latest report, stirring both optimism and concern among the suits at the table. Here's the brass tacks of it: a 9.5% boost in net revenue drumming up R$56.2 billion over twelve months. Sounds solid, huh? Yet, lurking...

Yeastar 2026 Summit: AI, Growth, and Global Vision

Reflecting on Two Decades of Innovation Yeastar's 20th anniversary summit in Xiamen was no ordinary gathering. It wasn't just about handshakes and business cards. Nope, it was a celebration intertwined with a deeper vision of growth and influence in the UCaaS space that Yeastar has carved out for itself over the years. Here's a company that's been plotting its course for...

TruGreen Boosts Military Discount, Joins 'Military Makeover'

Lawn Care with a Heart Look, a lot of us grumble about mowing the grass, but TruGreen's turning lawn care into something with a little more meaning. This Veterans Day, they're not just about keeping those blades of grass in check. No, they're honoring the folks who've served this country. Their military discount just doubled from 10% to 20% through the end of November....

CGI Shines with Strong Q4, Announces Dividend Hike

CGI Records Impressive Fourth Quarter Growth Well, CGI's got reason to strut its stuff this time around. Clocked in with a fourth-quarter revenue of $4.15 billion - that's a nice 3.3% bump up year-over-year, if you leave the currency noise out of it, it's about 2.5%. The real kicker? Net earnings shot up 20.8%. In a world where everyone’s fighting over scraps, these...